SCHEMBL4814933

SCHEMBL4814933

CC(C)Oc1ccc2c(c1)Cc1c(-c3ccc(C#N)nc3)n[nH]c1-2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 20/20 0.67
MARK3 P27448 4/20 0.61
RPS6KA3 P51812 4/20 0.61
AURKB Q96GD4 4/20 0.61
RPS6KB1 P23443 3/20 0.61
FLT3 P36888 3/20 0.61
AURKA O14965 1/20 0.61
JAK2 O60674 1/20 0.61
CHEK2 O96017 1/20 0.61
CSF1R P07333 1/20 0.61
MELK Q14680 3/20 0.56
MARK2 Q7KZI7 3/20 0.56
MAP4K4 O95819 2/20 0.56
PRKAA1 Q13131 2/20 0.56
RET P07949 2/20 0.56
BRSK1 Q8TDC3 2/20 0.56
PHKG2 P15735 1/20 0.56
MINK1 Q8N4C8 1/20 0.56
CDK2 P24941 2/20 0.55
IKBKB O14920 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816718 0.88 CHEK1 (0.80) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4817961 0.86 CHEK1 (0.64) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4815220 0.82 CHEK1 (0.67) CHEK1KDR
SCHEMBL4811749 0.81 CHEK1 (0.68) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4815954 0.81 CHEK1 (1.00) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4809009 0.80 CHEK1 (0.80) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4807586 0.80 CHEK1 (1.00) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4814017 0.80 CHEK1 (0.76) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4813279 0.80 CHEK1 (0.65) CHEK1MARK3RPS6KA3AURKBRPS6KB1
SCHEMBL4817862 0.80 CHEK1 (0.65) CHEK1MARK3RPS6KA3AURKBRPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US claimed
EP-1603885-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2005-12-14 EP claimed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US claimed
WO-2004080973-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-23 WO claimed
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 CHEK1 73/4885MARK3 496/4885RPS6KA3 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.